Fig. 8

GPR65 knockdown or HMGB1 inhibition mitigates malignant progression of glioma in vivo. A In a subcutaneous xenograft tumor model, the tumor volumes were measured and monitored every 7 days from each group of mice. (n = 4/group). B The pictures of corresponding subcutaneous xenograft tumors dissected from each group mice at 42 days post-injection. C Tumor weights from each group at 42 days post-injection. D Kaplan–Meier survival curve of each group mice of orthotopic glioma model (n = 6/group). E Representative images of IHC staining of HMGB1, Ki-67, Vimentin, N-cadherin, and E-cadherin in subcutaneous xenograft tumor. Data are presented as the Mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001